Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Operating Activities:
Net income	$ 2,806	$ 3,474
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,610	2,297
Stock-based compensation	1,671	1,899
Contingent consideration (gain) accretion expense	(174)	501
Unrealized foreign exchange (gain) loss	(473)	564
Deferred taxes	525	1,924
Gain on sale of strategic investment		(361)
Other	(25)	(18)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable	(223)	874
Inventories	132	(97)
Prepaids and other	(1,006)	9
Accounts payable and accrued liabilities	(1,959)	439
Income taxes	358	(1,925)
Deferred revenue	21
Net cash provided by operating activities	4,263	9,580
Investing Activities:
Purchases of property and equipment	(2,866)	(983)
Purchases of available-for-sale securities	(40,051)
Maturities of available-for-sale securities	27,071
Cash proceeds from sales of property and equipment		15
Cash received from sale of strategic investment		361
Payments for acquisitions, net of cash acquired		(25,149)
Net cash used in investing activities	(15,846)	(25,756)
Financing Activities:
Issuance of common stock	188	225
Payments for taxes related to net share settlement of equity awards	(2,127)	(366)
Payment of deferred financing costs	(97)
Payment of contingent consideration		(305)
Net cash used in financing activities	(2,036)	(446)
Effect of exchange rate changes on cash and cash equivalents	(109)	23
Net change in cash and cash equivalents	(13,728)	(16,599)
Cash and Cash Equivalents:
Beginning of period	24,987	55,588
End of period	11,259	38,989
Supplemental Information:
Cash paid for income taxes	1,881	2,486
Noncash transactions from investing and financing activities:
Acquisition of property and equipment on account	303	99
Issuance of performance shares, restricted and deferred stock units	$ 2,414	1,327
Creagh Medical Ltd and NorMedix Inc [Member]
Noncash transactions from investing and financing activities:
Contingent consideration and debt assumed in Creagh Medical and NorMedix transactions		$ 13,374